A Fernández-Clotet
A5079935064- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Diverticular Disease and Complications
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Celiac Disease Research and Management
- Diagnosis and treatment of tuberculosis
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Screening and Detection
- Pregnancy and Medication Impact
- Biosimilars and Bioanalytical Methods
- Helicobacter pylori-related gastroenterology studies
- Pharmaceutical studies and practices
- Gastrointestinal disorders and treatments
- Gastrointestinal Tumor Research and Treatment
- Pharmacological Effects of Natural Compounds
- Reproductive System and Pregnancy
- Anorectal Disease Treatments and Outcomes
- Systemic Lupus Erythematosus Research
- Gastrointestinal Bleeding Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Immune Cell Function and Interaction
- Appendicitis Diagnosis and Management
- Tuberculosis Research and Epidemiology
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2018-2025
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2018-2025
Hospital Clínic de Barcelona
2018-2025
Centro de Investigación Biomédica en Red
2021-2025
RELX Group (United States)
2023-2024
Universitat de Barcelona
2022
Hospital Del Mar
2016-2018
Parc de Salut
2014
Abstract Artificial Intelligence ( ai ) systems are precious support for decision-making, with many applications also in the medical domain. The interaction between md s and enjoys a renewed interest following increased possibilities of deep learning devices. However, we still have limited evidence-based knowledge context, design, psychological mechanisms that craft an optimal human– collaboration. In this multicentric study, 21 endoscopists reviewed 504 videos lesions prospectively acquired...
To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] real life.Patients from prospectively maintained ENEIDA registry treated with due to active UC were included. Clinical activity defined based on Partial Mayo Score [PMS]. Short-term response/remission was assessed at Weeks 4, 8, 16.A total 113 patients They exposed for a median time 44 weeks. Response remission Week 8 60% 31%, respectively. In multivariate analysis, higher PMS 4 (odds ratio [OR] = 0].2; 95%...
The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed clinical practice. We aimed to evaluate the durability, effectiveness, and safety UC real life.Patients included prospectively maintained ENEIDA registry, who received at least one intravenous dose due active [Partial Mayo Score [PMS]>2], were included. Clinical activity effectiveness defined based on PMS. Short-term response was assessed Week 16.A total 95...
Abstract Background Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by periods of relapse and remission. Current treatment options aim to achieve mucosal healing sustain long-term remission, yet many patients experience failure. Filgotinib (FIL), selective JAK1 inhibitor, has emerged as promising therapeutic agent in UC management with favorable outcomes clinical trials. This study aimed evaluate the real-world efficacy safety FIL moderate-to-severe UC. Methods We...
Summary Background There are limited data of ustekinumab administered according to the doses recommended in UNITI studies. Aim To assess real‐world, short‐term effectiveness refractory Crohn's disease (CD) Methods Multicentre study CD patients starting after June 2017 at recommend dose (260, 390 or 520 mg based on weight ~6 mg/kg IV week 0 and 90 subcutaneously 8). Values for Harvey‐Bradshaw Index (HBI), C‐reactive protein (CRP) faecal calprotectin (FC) were recorded baseline weeks 8 14....
Summary Background Data on the long‐term administration of ustekinumab in recommended doses are limited. Aim To assess real‐world, effectiveness refractory Crohn's disease (CD). Methods Multi‐centre study CD patients starting at dose, followed for 1 year. Values Harvey‐Bradshaw Index (HBI), endoscopic activity, C‐reactive protein (CRP), and faecal calprotectin (FC) were recorded baseline weeks 26 52. Demographic clinical data, previous treatments, adverse events (AEs) hospitalisations...
Accurate in-vivo optical characterization of colorectal polyps is key to select the optimal treatment regimen during colonoscopy. However, reported accuracies vary widely among endoscopists. We developed a novel intelligent medical device able seamlessly operate in real-time using conventional white light (WL) endoscopy video stream without virtual chromoendoscopy (blue light, BL). In this work, we evaluated standalone performance computer-aided diagnosis (CADx) on prospectively acquired...
Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics management PSC IBD patients, factors malignancies. Methods patients were identified from Spanish ENEIDA registry GETECCU. Additional data collected using AEG-REDCap electronic capture...
Summary Background In Crohn's disease, it is essential to distinguish between persistent damage and abnormalities that can heal with anti‐inflammatory therapy. Aim To assess magnetic resonance enterography (MRE) lesions persist in patients long‐standing endoscopic remission, analyse their relationship baseline characteristics, determine prognostic implications. Methods We systematically reviewed pre‐ post‐treatment MRE findings disease severe inflammation (segmental CDEIS ≥ 7 or ulcers at...
Background There is limited evidence on the effectiveness of biological therapy in stricturing complications patients with Crohn’s disease. Aim The study aims to determine anti‐tumor necrosis factor (TNF) agents disease complicated symptomatic strictures. Methods In this multicentric and retrospective study, we included adult receiving their first anti‐TNF therapy, no previous history biological, endoscopic or surgical therapy. agent was defined as a composite outcome combining steroid‐free...
Identifying predictors of therapeutic response is the cornerstone personalised medicine.To identify long-term healing severe inflammatory lesions based on magnetic resonance enterography (MRE) findings in patients with Crohn's disease (CD) treated tumour necrosis factor alpha (TNF-α) inhibitors.This prospective longitudinal single-centre study included clinically active CD requiring treatment TNF-α inhibitors at least one intestinal segment a lesion detected by MRE (segmental MaRIA ≥11)....
Magnetic resonance enterography (MRE) depicts transmural changes in response to biological treatment for Crohn's disease (CD); however, the long-term prognostic significance of these findings is unknown. The primary objective this study was identify on MRE 46 weeks after initiating that predict adverse outcomes.
Abstract Background The terminal ileum stands out as the most frequently affected segment of gastrointestinal tract in Crohn’s disease (CD). However, ileocolonoscopy (IC) may occasionally fail to fully explore this area. Assessing inflammation activity only lead underestimating overall ileal involvement. Capsule endoscopy (CE) offers a complete examination both entire and proximal segment. Methods This study presents preliminary analysis an ongoing multicenter retrospective conducted at 16...
Abstract Background Although the concept of postoperative recurrence (POR) in Crohn’s disease (CD) has been limited to patients undergoing intestinal resection with anastomosis, some small-sized retrospective series short follow-up periods suggest that clinical POR may occur up 30% a definitive ostomy. This explain lack recommendations for monitoring and preventive strategies this setting. Our aim was assess risk current population. Methods Retrospective study from ENEIDA database GETECCU....
Abstract Background For children born to mothers with inflammatory bowel disease (IBD), the effects of maternal inflammation and exposure biologic drugs during pregnancy may be significant. Elevated systemic markers are linked adverse birth outcomes impaired infant growth. However, specific evaluation within IBD context remains limited, impact drug on early anthropometric is still uncertain. Aim: analyze development malnutrition risk first year life based intrauterine breastfeeding biologics...
Abstract Background About 25% of Crohn’s disease (CD) patients develop perianal fistulizing (PFD), the pathogenesis which remains poorly understood. Here we aimed to characterise molecular and cellular events underlying this complication. Methods Non-inflamed rectal biopsies from CD with or without PFD (CD-PFD CD) were processed for single-cell (n=14) bulk (n=20) RNA analysis. Functional experiments conducted on human primary intestinal fibroblasts peripheral T cells. Results Single-cell...
Background and study aims: Previous studies have reported that diabetes mellitus is an independent risk factor for inadequate bowel preparation. Current guidelines do not recommend a specific preparation this patient population. The aims of were to assess the efficacy, safety, tolerability adapted protocol colon cleansing in patients with type 2 mellitus. Patients methods: This randomized, single-blind, parallel group, superiority trial compared conventional (CBP) diabetes-specific (DSP)....
Gadolinium-enhanced sequences are not included in the simplified Magnetic Resonance Index of Activity [sMARIA], but derivation this index readers had access to these sequences. The current study aimed validate sMARIA without gadolinium-enhanced for assessing disease activity, severity, and response treatment patients with Crohn's disease.We prospectively active at least one segment severe inflammation [ulcers] ileocolonoscopy, who required biologic drugs. Patients were evaluated by both...
INTRODUCTION: The objective of this study was to assess the durability, short-term and long-term effectiveness, safety tofacitinib in ulcerative colitis (UC) clinical practice. METHODS: This is a retrospective multicenter including patients with UC who had received first dose at least 8 weeks before inclusion. Clinical effectiveness based on partial Mayo score. RESULTS: A total 408 were included. Of them, 184 (45%) withdrew during follow-up (mean = 18 months). probability maintaining 67% 6...